Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen to Open New Facilities in US, Germany

NEW YORK, Nov. 22 - Qiagen has announced plans to construct two new facilities in Germany and Maryland to help ramp up production capacity, a company official told GenomeWeb.

 

When completed, the facilities will cost the Venlo, Netherlands-based genomics company $80 million and employ some 1,300 staff.

 

The first facility, in Germantown, Md., will cost $40 million when completed and will span 20,000 square meters, said Solveigh Karola Mahler, an investor relations manager at Qiagen, in a recent interview. Scheduled officially to open on Jan. 11, 2002, the facility will be home initially to between 50 and 100 individuals. Mahler projects that the number will eventually expand to roughly 200 production employees and 100 research and development workers.

 

The space will be used to produce and store Qiagen's acid tests, buffers, and other solutions for the North American and Japanese markets, the spokeswoman said. These markets represent 70 percent of Qiagen's revenue, Mahler said.

 

The facility in Germany, in the northern city of Hilden, will comprise one building for administrators and another for manufacturing and is intended to add to current manufacturing capabilities and replace current leases.

 

The buildings, which will initially take up 40,000 square meters that will grow to 60,000 square meters by around 2003, will also cost $40 million when completed. Staff are expected to begin moving in in mid-2002, said Mahler.

 

The Linden space will employ 700 people initially: 200 production staff, 250 research and development scientists, 100 salespeople, 100 administrators, and 50 marketing staff. Some 300 more staff will be hired by 2003 bringing to 1,000 the total number of employees there.

 

The facilities in Germany and Maryland will be paid primarily from loans and Qiagen's cash reserves.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.